Provided by Tiger Trade Technology Pte. Ltd.

Pfizer

28.00
+0.50001.82%
Pre-market: 28.00-0.0014-0.01%04:27 EDT
Volume:31.23M
Turnover:874.14M
Market Cap:159.20B
PE:36.85
High:28.17
Open:27.62
Low:27.55
Close:27.50
52wk High:29.21
52wk Low:23.62
Shares:5.69B
Float Shares:5.64B
Volume Ratio:1.00
T/O Rate:0.55%
Dividend:1.72
Dividend Rate:6.14%
EPS(TTM):0.7599
EPS(LYR):1.36
ROE:5.01%
ROA:5.78%
PB:1.87
PE(LYR):20.52

Loading ...

Major Drugmakers Turn to China for Licensing Deals

Reuters
·
Oct 02

Sanofi, Regeneron's Dupixent Successors Might Fall Short of Rivals

Dow Jones
·
Oct 02

Novartis Bets $7.8 Billion On MRNA Beyond Vaccines

Options & Short Sell
·
Oct 02

Jefferies Sticks to Their Buy Rating for Pfizer (PFE)

TIPRANKS
·
Oct 02

UBS Sticks to Their Hold Rating for Pfizer (PFE)

TIPRANKS
·
Oct 02

Pfizer : Jefferies Raises Target Price to $35 from $34

THOMSON REUTERS
·
Oct 02

Pfizer Inc. Stock Outperforms Competitors Despite Losses on the Day

Dow Jones
·
Oct 02

Trump Medicare Drug Pricing Model May Apply to Only Four Companies After Exemptions

Reuters
·
Oct 02

Sector Update: Healthcare

MT Newswires Live
·
Oct 02

Pfizer Sued by Florida Attorney General Over Alleged Deceptive Marketing Practices

MT Newswires Live
·
Oct 01

Florida sues Pfizer over COVID vaccine marketing

TIPRANKS
·
Oct 01

Florida Attorney General: Files Lawsuit Against Pfizer and Its CEO Albert Bourla

THOMSON REUTERS
·
Oct 01

Pfizer says Phase 2 study of tilrekimig met primary endpoint

TIPRANKS
·
Oct 01

Pfizer Says Tilrekimig Hits Phase 2 Atopic Dermatitis Endpoint with 62.5% EASI-75 at Week 16

Reuters
·
Oct 01

Pfizer - no Serious Adverse Events Related to Tilrekimig in Phase 2 Study

THOMSON REUTERS
·
Oct 01

Pfizer's Tilrekimig Shows Significant Skin Clearance in Phase 2 Atopic Dermatitis Study

THOMSON REUTERS
·
Oct 01

Pfizer - Tilrekimig Well-Tolerated with Teae Rates Comparable to Placebo

THOMSON REUTERS
·
Oct 01

Pfizer - 62.5% of Patients on Tilrekimig 450 Mg Q2w Achieve Easi-75 vs 19.9% Placebo

THOMSON REUTERS
·
Oct 01

Pfizer - Phase 2 Study Meets Primary Endpoint with Significant Easi-75 Improvement at Week 16

THOMSON REUTERS
·
Oct 01

23% Weight Loss, 27% Dropouts: How Strong Is Lilly's Phase 2 Combo, Really?

Options & Short Sell
·
Oct 01